Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.

NCT03905343 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03905343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03905343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line Treatment in Patients With Visceral Metastatic Breast Cancer. A Multicenter, Randomized Phase III Trial.
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Terminated
Start date
June 25, 2019
Completion date
April 15, 2021
Enrollment
25 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer